
CLAIMS

What is claimed is:

1. Use of Compound A



(Compound A)

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of narcolepsy or idiopathic hypersomnia wherein the Compound A or the pharmaceutically acceptable salt thereof is to be administered orally once or more per day.

2. The use according to claim 1, wherein the Compound A or the pharmaceutically acceptable salt thereof is to be administered orally once per day.

3. The use according to claim 1 or 2, wherein the Compound A or the pharmaceutically acceptable salt thereof has a volume based particle size with a Dv90 of between about 5 and about 200 microns as determined by a light scattering technique.

4. The use according to any one of claims 1 to 3, wherein the oral administration is to provide a C_{max} of the Compound A of between about 5 ng/mL and about 35 ng/mL and a half-life ($t_{1/2}$) of the Compound A between about 4 and about 12 hours; and wherein the plasma concentration for the Compound A following oral administration is about 3.0 ng/mL or more at 2 hours after administration and about 1.0 ng/mL or less at 12 hours after administration.

5. The use according to any one of claims 1 to 4, wherein the Compound A or the pharmaceutically acceptable salt thereof is to be administered at a daily dose of from about 1 mg to about 25 mg.

6. The use according to any one of claims 1 to 4, wherein the narcolepsy is narcolepsy type 1.

7. The use according to claim 6, wherein the Compound A or the pharmaceutically acceptable salt thereof is to be administered at a daily dose of from about 1 mg to about 10 mg.


8. The use according to any one of claims 1 to 4, wherein the narcolepsy is narcolepsy type 2.

9. The use according to claim 8, wherein the Compound A or the pharmaceutically acceptable salt thereof is to be administered at a daily dose of from about 8 mg to about 25 mg.

10. The use according to any one of claims 1 to 4, in the manufacture of the medicament for the treatment of idiopathic hypersomnia.

11. The use according to claim 10, wherein the Compound A or the pharmaceutically acceptable salt thereof is to be administered at a daily dose of from about 8 mg to about 25 mg.

12. A pharmaceutical composition comprising a pharmaceutically active compound or a pharmaceutically acceptable salt thereof in an amount of from about 0.5 mg to about 50 mg, wherein the pharmaceutically active compound is Compound A:



(Compound A)

or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition according to claim 12, wherein the composition is adapted for administration once, twice or three times daily.

14. The pharmaceutical composition according to claim 12 or 13 wherein the pharmaceutically active compound is present in the form of particles having a Dv90 of between about 5 microns and about 200 microns as determined by a light scattering technique.

15. The pharmaceutical composition according to claim 14, wherein the pharmaceutically active compound is present in the form of particles having a Dv90 of 12 microns ±25% as determined by a light scattering technique, or a specific surface area of 10 m^2/g ± 25% as measured by the BET method.